Cognitive Screening in Risk Assessment. Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University.

Similar documents
Overview. Case #1 4/20/2012. Neuropsychological assessment of older adults: what, when and why?

Mild Cognitive Impairment (MCI)

Mild Cognitive Impairment in the General Population: Occurrence and progression to Alzheimer s disease

Service Related Project. Kimberley Keegan

Neuropsychological Evaluation of

UDS version 3 Summary of major changes to UDS form packets

ALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health

NEUROPSYCHOMETRIC TESTS

Recognizing Dementia can be Tricky

Korean-VCI Harmonization Standardization- Neuropsychology Protocol (K-VCIHS-NP)

DEMENTIA, THE BRAIN AND HOW IT WORKS AND WHY YOU MATTER

I IADL. See Instrumental activities of daily living (IADL) Idiopathic rapid eye movement sleep behavior disorder (Idiopathic RBD), 136

Cognitive Impairment. Don t Forget It. July 10, Genworth Financial, Inc. All rights reserved.

Identification of Cognitive Impairment in HIV patients. Belinda Vicioso MD FACP, AGSF Jose Garcia Professor of Medicine UTSW

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient

Assessment of People with Early Dementia and their Families

Erin Cullnan Research Assistant, University of Illinois at Chicago

David A Scott Lis Evered. Department of Anaesthesia and Acute Pain Medicine St Vincent s Hospital, Melbourne University of Melbourne

Alzheimer s disease dementia: a neuropsychological approach

Form D1: Clinician Diagnosis

MOS SF-36 health survey (Ware &

Form A3: Subject Family History

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE

Understanding Dementia

AD Prevention Trials: An Industry Perspective

CRITICALLY APPRAISED PAPER (CAP)

Why Cognition Matters: Impact of Cognitive Impairment on Safety and Independent Living Skills

Clinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)

Index. Addenbrooke s cognitive examination (ACE)

Assessing cognitive function after stroke. Glyn Humphreys

Dementia. Aetiology, pathophysiology and the role of neuropsychological testing. Dr Sheng Ling Low Geriatrician

AGED SPECIFIC ASSESSMENT TOOLS. Anna Ciotta Senior Clinical Neuropsychologist Peninsula Mental Health Services

Assessing and Managing the Patient with Cognitive Decline

DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease

Aging: Tools for Assessment

Can aspirin slow cognitive decline and the onset of dementia? The ASPREE study. Mark Nelson on behalf of ASPREE Investigators

I n the past three decades various cognitive screening

The current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease

Evaluations & CE Credits

Objectives. My Patient: The story 10/6/2017

Alzheimer's Disease Brain Failure, Stopping the Momentum. Katherine E. Galluzzi, DO, CMD, FACOFP dist.

Screening for Cognitive Impairment

The Cognitive Log (Cog-Log) & The Orientation Log (O-Log)

CTFPHC Working Group Members:

AMNESTIC MINIMAL COGNITIVE IMPAIRMENT: BEYOND MEMORY

Quality ID #291: Parkinson s Disease: Cognitive Impairment or Dysfunction Assessment National Quality Strategy Domain: Effective Clinical Care

Montreal Cognitive Assessment (MoCA) Overview for Best Practice in Stroke and Complex Neurological Conditions March 2013

ASHA Comments* (ASHA Recommendations Compared to DSM-5 Criteria) Austism Spectrum Disorder (ASD)

Cognitive Assessment 4/29/2015. Learning Objectives To be able to:

3/6/2019 DIAGNOSIS OF DEMENTIA IN THE OUTPATIENT SETTING FINANCIAL DISCLOSURES LEARNING OBJECTIVES

A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies

DSM-5 MAJOR AND MILD NEUROCOGNITIVE DISORDERS (PAGE 602)

Capacity and Older Adults. Kenneth I. Shulman

LANGUAGE AND COGNITIVE TASKS MOST PREDICTIVE OF MILD COGNITIVE IMPAIRMENT. A Thesis by Brooke Holt

Anxiety, Depression, and Dementia/Alzheimer Disease: What are the Links?

Dementia and Alzheimer s disease

BHIVA Best Practice Management Session

Draft for Consultation

SHARED CARE OF MCI/EARLY DEMENTIA

Overview of neurological changes in Alzheimer s disease. Eric Karran

HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?

Evaluations. Alzheimer s Disease A Public Health Response. Viewer Call-In. July 19, Guest Speakers. Thanks to our Sponsors:

ALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Currently Used Measures of Cognitive Impairment An HBRN Scholar Special Presentation & Discussion

An estimated half a million

Prof Tim Anderson. Neurologist University of Otago Christchurch

Test Assessment Description Ref. Global Deterioration Rating Scale Dementia severity Rating scale of dementia stages (2) (4) delayed recognition

Falls: Cognitive Motor Perspectives

Mild cognitive impairment A view on grey areas of a grey area diagnosis

What APS Workers Need to Know about Frontotemporal, Lewy Body and Vascular Dementias

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia

Screening and Case Finding Tools for the Detection of Dementia. Part I: Evidence- Based Meta-Analysis of Multidomain Tests

Practical Matters in the Care of A Person with Dementia

Geriatric Grand Rounds

02/04/2015. The structure of the talk. Dementia as a motor disorder. Movement, cognition & behaviour. Example 1. Example 2

Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues

Evaluation and Treatment of Dementia

International Forum on HIV and Rehabilitation Research

Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia

Brain Health and Risk Factors for Dementia

Does This Patient Have Dementia?

Mild Cognitive Impairment

Damian, Anne Mariam. The University of Arizona.

Assessment Toolkits for Lewy Body Dementia

Alzheimer s Disease and Related Disorders: The Public Health Call to Action

NUMERATOR: All patients with a diagnosis of Parkinson s Disease who were assessed for cognitive impairment or dysfunction in the past 12 months

SUPPLEMENTAL MATERIAL

Recommendations on Screening for Cognitive Impairment in Older Adults 2015

Malaysian Healthy Ageing Society

ORIGINAL ARTICLE Neuroscience INTRODUCTION MATERIALS AND METHODS

January 18 th, 2018 Brixen, Italy

A report for the UK National Screening Committee

COGNITIVE ALTERATIONS IN CHRONIC KIDNEY DISEASE K K L E E

Diagnosis and Treatment of Alzhiemer s Disease

Exploration of a weighed cognitive composite score for measuring decline in amnestic MCI

THE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME

Minimizing Misdiagnosis: Psychometric Criteria for Possible or Probable Memory Impairment

Mining for Lost Memories: A Best Practice Approach for Alzheimer s Disease Diagnosis

Information Gathering Obtaining history is the most critical first step Patient-provided history may not be reliable Need info from relatives, friends

Transcription:

Cognitive Screening in Risk Assessment Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University Outline of Talk Definition of Dementia and MCI Incidence and Prevalence of Dementia and Mild Cognitive Impairment Cognitive Screening Tests Factors that Impact Screening Tests Review Strengths and Weaknesses of Specific Screening Tests 1

Diagnostic Criteria for Dementia of the Alzheimer s Type (DSM-IV) Development of multiple cognitive deficits including Memory impairment One or more of the following Aphasia Apraxia Agnosia Executive dysfunction Cognitive deficits cause significant impairment in social or occupational functioning and represent a significant decline from a previous level of functioning Gradual onset and continuing cognitive decline Not due to Other CNS conditions (e.g., cerebrovascular disease, Parkinson s disease Systemic conditions (e.g., thyroid, B-12 deficiency) Substance-induced conditions Diagnostic Criteria Mild Cognitive Impairment (MCI; Peterson et al. 2001) Memory complaint best if corroborated by informant Objective evidence of cognitive impairment (>1.5 SDs normative data) Minimal or no functional decline Subtypes Amnestic Amnestic plus Non-Amnestic Single domain Non-Amnestic Multi-domain Conversion to dementia 12-15% per year (1-2% normal elderly; 5-10 times normal risk) 80% of MCI may eventually develop dementia 2

Cognitive Complaint * Not normal for age *Not demented *Cognitive Decline * Essentially normal functional activities MCI Yes Amnestic MCI Is memory impaired? No Non- Amnestic MCI Memory Single nonmemory domain impairment only? Yes No Yes No impairment? Amnestic MCI Single Domain (Associated with AD and Depression) Adapted from Petersen & Negash, 2008 Amnestic Plus MCI (Associated with AD, Vascular Dementia and Depression) Non-Amnestic MCI Single Domain (Associated Fronto- Temporal Dementia) Non-Amnestic MCI Multi Domain (Associated dementia with Lewy bodies) 5.2 million 3

MCI Prevalence Not clear because of varying definitions Age-Associated Memory Impairment Cognitive Disorder NOS Cognitive Disorder, No Dementia Study of 1,969 individuals 70-89 years old (Petersen et al., 2010) 16% MCI 11.1% amnestic MCI 4.9% non-amnestic MCI Higher in older, men, non-married, APOE 3,4 or 4,4 Higher risk associated with lower levels of education 4

Dementia Risk Factors Increase Risk Age Family history APOE e4 allele Mild Cognitive Impairment Cardiovascular disease risk smoking, diabetes, obesity, high cholesterol, hypertension Traumatic Brain Injury (moderate-severe) Decrease Risk Education APOE e2 allele Physical Activity Diet (Mediterranean) 5

Life Expectancy in Dementia 500,000 die each year 6 th leading cause of death for 65 and older Kills more than prostate and breast cancer 65 and older survive 4-8 years after diagnosis Some can live 20 years or more COGNITIVE SCREENING FOR MCI AND DEMENTIA 6

Cognitive Screening Test Brief measure to identify individuals with cognitive impairment Efficiency Convenience Early identification Easy to administer by non-professional personnel Could be implemented on a wide scale or in routine practice US Preventive Services Task Force Routine screening for dementia in older adults found good evidence that some screening tests have good sensitivity but only fair specificity in detecting cognitive impairment and dementia the accuracy of diagnosis, the feasibility of screening and treatment in routine clinical practice, and the potential harms of screening are unknown. The Task Force therefore could not determine whether the benefits of screening for dementia outweigh the harms. 7

Limitations of Screening Tests Not necessarily well validated in intended population (base rates) May not fully cover important cognitive domains (emphasize memory and do not address other domains executive function, language, etc. Not as accurate for mild impairment Implications of false positive errors Reliance on cut score rather than pattern of performance Not a substitute for a neuropsychological evaluation Key Cognitive Domains Attention/Working memory Digit Span Verbal/Visual learning and recall List learning Language Naming/Word Finding Visual construction Design copy Executive function & Abstract Reasoning Similarities 8

Test + Test - Test Accuracy Impaired A True Positive C False Negative Not Impaired B False Positive D True Negative Sensitivity = A/A+C; proportion of individuals with impairment who test positive Specificity = D/B+D; proportion of individuals without impairment who test negative Overall Accuracy = A+D/N; weighted average of sensitivity and specificity Positive Predictive Value = A/A+B; proportion of individuals who are classified as impaired who actually are impaired Negative Predictive Value = D/C+D; proportion of individuals who are classified as not impaired who actually are not impaired Test Accuracy cont. Maximize sensitivity and specificity Emphasize one over the other depending on situation and costs of false positive or false negative errors Sensitivity and specificity are intrinsic to test (not dependent on prevalence of condition) PPV and NPV depends on prevalence Lower PPV with lower prevalence 9

EXAMPLES Sensitivity = 90% Specificity = 90% Prevalence = 30% N =100 Impaired Not Impaired Test + 27 7 PPV = 84% NPV = 95% Test - 3 63 Sensitivity = 90% Specificity = 90% Prevalence = 5% N = 100 Impaired Not Impaired Test + 4 10 PPV = 29% NPV = 99% Test - 1 85 Overall Accuracy Misleading when: difference between sensitivity and specificity increase When prevalence deviates from 50% Adapted from Alberg et al., 2004; J Gen Intern Med 10

Common Cognitive Screening Measures Factors that Impact Screening Test Performance Age (begin at age 55; accelerates at 75) Education (IQ; low levels can result in misclassification Gender (little impact) Race/Language/Culture/Background Psychiatric/Mood (anxiety, depression) Medications 11

Mini Mental State Examination (MMSE) Strengths Commonly used and best studied Quick and easy to administer (7-8 min) Good normative data Weaknesses Does not address executive dysfunction Accuracy dependent on age and education Over-reliance on orientation and memory Heavily dependent on language Can misclassify individuals with low education Cost? Copyrighted? 12

MMSE cont. Dementia Sensivity = 71-92% Specificity = 56-96% PPV = 15-72% (10% prevalence) MCI Sen = 73-82% Spec = 55-73% Can improve MCI detection Combine other measures (e.g., verbal fluency) Use longer forms (3MS) MCI and Dementia Progression associated with Different MMSE levels 13

Montreal Cognitive Assessment (MoCA) Strengths Brief (10-12 min) Easy to administer/score Captures executive functioning More accurate than MMSE for MCI No cost Available in many languages Weaknesses Probably best for individuals with MMSE>26 May misclassify cognitively normal Less useful for overt dementia 14

MOCA cont. Dementia Sen = 100% Spec = 87% MCI Sen = 90% Spec = 87% Minnesota Cognitive Acuity Screen (MCAS; Knopman et al., 2000) Strengths Brief measure (15 min) In-person or by telephone 9 domains assessed: orientation, attention, delayed recall, comprehension, repetition, naming, computation, judgment, verbal fluency Detailed instructions/scoring No significant impact of age and education Data to support relationship with functioning 15

MCAS cont. Weaknesses Longer than MMSE and MOCA Dementia Sen = 98% Spec = 99% MCI Sen = 86% Spec = 78% Clock Drawing Test (CDT) Strengths Very brief Measures constructional, visuospatial, & executive skills Part of other screens (7-min screen) May be most sensitive to vascular dementia Less affected by education and culture/background 16

CDT cont Weaknesses Multiple administration/scoring versions Generally poor specificity Very poor for detecting MCI Dementia Sen = 39-94% Spec = 26-96% MCI Sen = 48-76% Spec = 58-79% Mild Cognitive Impairment 17

Alzheimer s Disease Lewy Body Dementia 18

Frontotemporal Dementia MCI Screen (Shankle et al., 2005) CERAD 10-word list w/weighted scoring Strengths Brief & easy to administer Weaknesses Focuses entirely on memory (Alzheimer s disease) Complex scoring process Costs Dementia Sen = 96% Spec = 99% MCI Sen = 95% Spec = 98% 19

7-Minute Screen Enhanced cued recall, temporal orientation, verbal fluency, clock drawing Strengths Brief (6-10 min) Easy to administer and score Weaknesses Not helpful for MCI Dementia Sen =91-93% Spec = 94-96% MCI Sen = 28% Spec =? Mini-Cog 3 word recall and Clock Drawing Test Strengths Very brief (3 min) Easy to administer Weaknesses Miss milder impairments Dementia Sen = 76-99% Spec = 89-93% MCI Sen = 55% Spec = 77% 20

AD8 Informant-based Measures Functional Activities Questionnaire (FAQ) Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) Better for dementia than MCI Sen & Spec ~ 90% for dementia Enhanced sensitivity and specificity when combined with cognitive screens Conclusions Screens can be useful for identifying individuals at risk for cognitive decline Consider base rates impact on PPV Not a substitute for through eval or workup Very brief screens may miss milder impairment (especially in highly educated individuals) Brief screens may not capture all important cognitive domains 21

Questions? 22